RE:RE:RE:RE:TauRx Article in The Scotsman
TauRx plans to submit HMTM for regulatory approval in the US and Canada in 2023, with other territories to follow, in line with its overall plans to commercialise HMTM and pursue clinical trials in other related neurodegenerative diseases.